Our study suggested that HDAC inhibitor and PI3k inhibitor decrease the proliferation of tamoxifen-resistant breast cancer through inhibition of the PI3k/Akt/mTOR signaling pathway. This evidence concerns the gene HDAC9 and breast cancer.